MedPath

Kava Kava for the Treatment of Generalized Anxiety Disorder (GAD)

Phase 2
Terminated
Conditions
Anxiety Disorders
Interventions
Registration Number
NCT00083980
Lead Sponsor
National Center for Complementary and Integrative Health (NCCIH)
Brief Summary

The purpose of this study is to evaluate the safety and effectiveness of the herbal medicine kava kava for the treatment of generalized anxiety disorder (GAD).

Detailed Description

Kava kava (KAV) is a plant-derived treatment widely used in Europe to treat anxiety disorders. Several studies suggest that KAV may be effective in reducing anxiety symptoms; however, trial data are limited. This study will compare KAV, the drug venlafaxine-XR (VEN), and placebo for the treatment of GAD.

This study will last 10 weeks. Participants will be randomly assigned to receive KAV, VEN, or placebo for 8 weeks. Participants will then undergo a 1-week tapering of their medication followed by an additional week of observation. Self-report scales and questionnaires will be used to assess the anxiety, depression, and functional impairment of participants. Side effects, vital signs, and laboratory measures will be monitored throughout the study.

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
16
Inclusion Criteria
  • Diagnosis of generalized anxiety disorder (GAD)
Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Herbal treatment kavaSugar pillKava
Sugar pillSugar pillInert placebo pills as duble dummy - up to 4 per day for kava and 3 per day for venlafaxine
active antidepressant drug comparatorSugar pillVenlafaxine ER
active antidepressant drug comparatorVenlafaxine ERVenlafaxine ER
Herbal treatment kavaKavaKava
Primary Outcome Measures
NameTimeMethod
Hamilton Anxiety Scale8 weeks
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath